Methodological aspects of phase-I studies of novel anticancer agents (review).
In the last 5 years we have performed 14 phase I studies in our department. Eight of these trials involved evaluation of both the clinical and the pharmacokinetic behaviour of novel anti-cancer agents. The remainder investigated various aspects of drug delivery, targetting or resistance modification with existing anti-cancer drugs. In total these studies have involved over 200 patients. In this review article we have drawn upon our experience to suggest guidelines for future studies.